CNS Pharmaceuticals, Inc. Annual Report - A Summary for Investors

I’m writing this guide to help you understand CNS Pharmaceuticals’ performance this year. My goal is to turn complex financial filings into plain English, helping you decide if this company fits your investment goals.

1. What does this company do and how did they perform?

CNS Pharmaceuticals is a biotech company based in Houston, Texas. They are in the research phase, meaning they have no products for sale and earn no revenue. They focus on developing treatments for brain cancers. Fiscal year 2025 was a year of major change. After clinical setbacks, the company hired Rami Levin as CEO in February 2026 to lead a restructuring. The new team is tasked with reversing the decline in shareholder value and identifying a viable path toward a marketable product.

2. The Big Pivot

The company is moving away from its legacy projects, specifically Berubicin for brain cancer and TPI 287 for neurodegenerative diseases. These programs previously consumed the majority of the research budget. CNS is now shelving these projects to preserve capital and is exploring options to sell or license them to other entities. The company is shifting to a "buy-to-build" model, where they intend to acquire or license existing treatments from other companies that are closer to regulatory approval.

3. Financial Health and the "Cash Runway"

CNS Pharmaceuticals is currently operating at a loss, reporting approximately $14.2 million in losses this year, primarily driven by research and administrative expenses. As of their last report, the company held about $3.8 million in cash. To maintain operations, the company issued additional shares to investors. This process, known as dilution, resulted in the total number of shares growing by over 40% this year, which reduces the ownership percentage of existing shareholders. Management indicates that current cash reserves are expected to last 6 to 9 months without additional capital raises.

4. Key Risks

• The "Pivot" Risk: Transitioning to a new business model is capital-intensive. There is a risk that newly acquired treatments may fail, which would deplete the company’s remaining cash.
• Dilution: With a monthly burn rate of approximately $1.1 million, the company will likely need to issue more shares to remain operational. This typically exerts downward pressure on the share price and further reduces individual ownership stakes.
• Clinical Success: The company’s valuation is based on future potential rather than current revenue. If future trials or acquisitions fail, the company lacks alternative products to sustain operations, which could result in a total loss of investment.
• Execution: The new leadership is operating under a strict timeline. They must secure a promising new asset within the next six months to avoid a liquidity crisis.

5. Future Outlook

The company is effectively repositioning itself as a vehicle for future biotech acquisitions. By hitting the "reset" button, they are attempting to move from a failed research model to a leaner, acquisition-focused strategy targeting the oncology and neurology markets. Success depends entirely on the new team’s ability to acquire a valuable asset before their cash reserves are exhausted, while balancing the share dilution that has impacted current shareholders.

Investor Takeaway: CNS Pharmaceuticals is currently a high-risk, speculative play. Because they have no revenue and a very short cash runway, your investment decision should focus on whether you believe the new management team can successfully execute their "buy-to-build" strategy before the company is forced to raise more capital. If you are risk-averse, the uncertainty surrounding their upcoming acquisitions and the ongoing dilution of shares are significant factors to consider.